Browsing by Author "Valdez, Hernán"

Now showing items 1-2 of 2

    • Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic ... 
      Blauvelt, Andrew; Silverberg, Jonathan I.; Lynde, Charles W.; Bieber, Thomas; Eisman, Samantha; Zdybski, Jacek; Gubelin, Walter; Simpson, Eric L.; Valenzuela Ahumada, Fernando Alfredo; Criado, Paulo Ricardo; Lebwohl, Mark G.; Feeney, Claire; Khan, Tahira; Biswas, Pinaki; DiBonaventura, Marco; Valdez, Hernán; Cameron, Michael C.; Rojo, Ricardo (Elsevier, 2022)
      Background: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. Objective: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib ...
    • Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised ... 
      Bachelez, Hervé; Kerkhof, Peter C. M. van de; Strohal, Robert; Kubanov, Alexey; Valenzuela, Fernando; Lee, Joo-Heung; Yakusevich, Vladimir; Chimenti, Sergio; Papacharalambous, Jocelyne; Proulx, James; Gupta, Pankaj; Tan, Huaming; Tawadrous, Margaret; Valdez, Hernán; Wolk, Robert (Elsevier, 2015)
      Background New therapeutic options are needed for patients with psoriasis. Tofacitinib, an oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe chronic plaque psoriasis. In this study, ...